NCT07080619RecruitingPhase 2
SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers
A Phase IIa Clinical Study to Assess the Efficacy and Safety of SC-101 in Patients With Advanced Malignant Tumors Positive for NECTIN4 Gene Amplification
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
This study is an open-label, multicenter Phase IIa trial to evaluate the efficacy and safety of SC-101 monotherapy in patients with locally advanced or metastatic malignant tumors who are positive for NECTIN4 gene amplification.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- First submitted
- 7 Jul 2025
- Start date
- 26 Aug 2025
- Primary completion date
- 30 Jul 2027
- Lead sponsor
- Tianjin ConjuStar Biologics Co., Ltd.
- Diseases
- Triple-negative breast cancer
- NCT number
- NCT07080619
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 120
- From 26 Aug 2025 to the primary completion date, 30 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Adverse reactions from previous anticancer treatments have not recovered to a CTCAE 5.0 grade ≤1.
Other illness
- A history of severe cardiovascular or cerebrovascular disease.
Other
- Unstable central nervous system tumors.
Who the study is looking for
- Age between 18 and 75 years (inclusive), regardless of gender.
- ECOG performance status of 0-1.
- Expected survival of more than 3 months, as assessed by the investigator.
- Fertile participants must agree to use contraception.
- Able to understand the trial requirements and willing and able to comply with the trial and follow-up procedures.
- Adequate bone marrow and organ function.
- NECTIN-4 gene amplification positive.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.